- Casirivimab/
imdevimab, sold
under the
brand name REGEN‑COV
among others, is a
combination medicine used for the
treatment and
prevention of COVID‑19....
-
monoclonal antibody therapies bamlanivimab/etesevimab and casirivimab/
imdevimab were
given emergency use
authorizations by the US Food and Drug Administration...
- "Casirivimab injection, solution,
concentrate Imdevimab injection, solution,
concentrate REGEN-COV –
casirivimab and
imdevimab kit". DailyMed.
Archived from the original...
- "Casirivimab injection, solution,
concentrate Imdevimab injection, solution,
concentrate REGEN-COV-
casirivimab and
imdevimab kit". DailyMed.
Retrieved 18 March...
- Bebtelovimab§ Casirivimab† (+
imdevimab) Cilgavimab† (+tixagevimab)† Diridavumab§ Etesevimab† Exbivirumab§ Foravirumab§
Imdevimab† (+casirivimab) Libivirumab§...
-
plasma in COVID-19 in
December 2021.
Monoclonal antibodies (casirivimab/
imdevimab) were
developed for the
treatment of COVID-19. On June 7, 2021, the FDA...
- 2021. "****an
becomes first country to
approve Ronapreve (casirivimab and
imdevimab) for the
treatment of mild to
moderate COVID-19".
Roche (Press release)...
-
treatments – bamlanivimab/etesevimab (administered together) and casirivimab/
imdevimab – to
limit their use to only when the
recipients are
likely to have been...
- on its own. At high
enough concentrations, casirivimab,
etesevimab and
imdevimab appear to
still be effective. A
preprint study suggests that sotrovimab...
-
monoclonal antibody therapies bamlanivimab/etesevimab and casirivimab/
imdevimab were
found to
reduce the
number of hospitalizations,
emergency room visits...
